Bone Biologics (BBLGW) Notes Payables (2013 - 2021)

Bone Biologics (BBLGW) has reported Notes Payables for 9 consecutive years, with $12.8 million the latest figure, recorded in Q3 2021.

• On a quarterly basis, Notes Payables rose 10.07% year-over-year to $12.8 million in Q3 2021; TTM through Sep 2021 was $12.8 million, a 10.07% increase from a year earlier, with the FY2020 full-year figure at $11.7 million, changed N/A from the prior year.
• Notes Payables was $12.8 million for Q3 2021 at Bone Biologics, up from $12.5 million in the prior quarter.
• Over five years, Notes Payables peaked at $12.8 million in Q3 2021 and troughed at $600000.0 in Q2 2018.
• A 5-year average of $8.7 million and a median of $11.2 million in 2019 frame the typical range for Notes Payables.
• Across the five-year window, Notes Payables sank 71.55% in 2018 and surged 1683.33% in 2019, its largest moves.
• Over 5 years, Notes Payables stood at $2.9 million in 2017, then jumped by 211.65% to $9.0 million in 2018, then advanced by 24.44% to $11.2 million in 2019, then gained by 4.57% to $11.7 million in 2020, then grew by 9.01% to $12.8 million in 2021.
• The last three Notes Payables figures came in at $12.8 million (Q3 2021), $12.5 million (Q2 2021), and $11.9 million (Q1 2021), per Business Quant data.